Robot-assisted Radical Cystectomy with Orthotopic Neobladder Reconstruction: Techniques and Functional Outcomes in Males.


Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
11 2023
Historique:
received: 23 01 2023
revised: 25 02 2023
accepted: 03 04 2023
medline: 23 10 2023
pubmed: 29 4 2023
entrez: 28 4 2023
Statut: ppublish

Résumé

Little is known regarding functional outcomes after robot-assisted radical cystectomy (RARC) and intracorporeal neobladder (ICNB) reconstruction. To report on urinary continence (UC) and erectile function (EF) at 12 mo after RARC and ICNB reconstruction and investigate predictors of these outcomes. We used data from a multi-institutional database of patients who underwent RARC and ICNB reconstruction for bladder cancer. The cystoprostatectomy sensu stricto followed the conventional steps. ICNB reconstruction was performed at the physician's discretion according to the Studer/Wiklund, S pouch, Gaston, vescica ileale Padovana, or Hautmann technique. The techniques are detailed in the video accompanying the article. The outcomes measured were UC and EF at 12 mo. A total of 732 male patients were identified with a median age at diagnosis of 64 yr (interquartile range 58-70). The ICNB reconstruction technique was Studer/Wiklund in 74%, S pouch in 1.5%, Gaston in 19%, vescica ileale Padovana in 1.5%, and Hautmann in 4% of cases. The 12-mo UC rate was 86% for daytime and 66% for nighttime continence, including patients who reported the use of a safety pad (20% and 32%, respectively). The 12-mo EF rate was 55%, including men who reported potency with the aid of phosphodiesterase type 5 inhibitors (24%). After adjusting for potential confounders, neobladder type was not associated with UC. Unilateral nerve-sparing (odds ratio [OR] 3.85, 95% confidence interval [CI] 1.88-7.85; p < 0.001) and bilateral nerve-sparing (OR 6.25, 95% CI 3.55-11.0; p < 0.001), were positively associated with EF, whereas age (OR 0.93, 95% CI 0.91-0.95; p < 0.001) and an American Society of Anesthesiologists score of 3 (OR 0.46, 95% CI 0.25-0.89; p < 0.02) were inversely associated with EF. RARC and ICNB reconstruction are generally associated with good functional outcomes in terms of UC. EF is highly affected by the degree of nerve preservation, age, and comorbidities. We investigated functional outcomes after robot-assisted removal of the bladder in terms of urinary continence and erectile function. We found that, in general, patients have relatively good functional outcomes at 12 months after surgery.

Sections du résumé

BACKGROUND
Little is known regarding functional outcomes after robot-assisted radical cystectomy (RARC) and intracorporeal neobladder (ICNB) reconstruction.
OBJECTIVE
To report on urinary continence (UC) and erectile function (EF) at 12 mo after RARC and ICNB reconstruction and investigate predictors of these outcomes.
DESIGN, SETTING, AND PARTICIPANTS
We used data from a multi-institutional database of patients who underwent RARC and ICNB reconstruction for bladder cancer.
SURGICAL PROCEDURE
The cystoprostatectomy sensu stricto followed the conventional steps. ICNB reconstruction was performed at the physician's discretion according to the Studer/Wiklund, S pouch, Gaston, vescica ileale Padovana, or Hautmann technique. The techniques are detailed in the video accompanying the article.
MEASUREMENTS
The outcomes measured were UC and EF at 12 mo.
RESULTS AND LIMITATIONS
A total of 732 male patients were identified with a median age at diagnosis of 64 yr (interquartile range 58-70). The ICNB reconstruction technique was Studer/Wiklund in 74%, S pouch in 1.5%, Gaston in 19%, vescica ileale Padovana in 1.5%, and Hautmann in 4% of cases. The 12-mo UC rate was 86% for daytime and 66% for nighttime continence, including patients who reported the use of a safety pad (20% and 32%, respectively). The 12-mo EF rate was 55%, including men who reported potency with the aid of phosphodiesterase type 5 inhibitors (24%). After adjusting for potential confounders, neobladder type was not associated with UC. Unilateral nerve-sparing (odds ratio [OR] 3.85, 95% confidence interval [CI] 1.88-7.85; p < 0.001) and bilateral nerve-sparing (OR 6.25, 95% CI 3.55-11.0; p < 0.001), were positively associated with EF, whereas age (OR 0.93, 95% CI 0.91-0.95; p < 0.001) and an American Society of Anesthesiologists score of 3 (OR 0.46, 95% CI 0.25-0.89; p < 0.02) were inversely associated with EF.
CONCLUSIONS
RARC and ICNB reconstruction are generally associated with good functional outcomes in terms of UC. EF is highly affected by the degree of nerve preservation, age, and comorbidities.
PATIENT SUMMARY
We investigated functional outcomes after robot-assisted removal of the bladder in terms of urinary continence and erectile function. We found that, in general, patients have relatively good functional outcomes at 12 months after surgery.

Identifiants

pubmed: 37117109
pii: S0302-2838(23)02728-8
doi: 10.1016/j.eururo.2023.04.009
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

484-490

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

Alberto Martini (A)

Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France.

Ugo Giovanni Falagario (UG)

Department of Urology and Organ Transplantation, University of Foggia, Foggia, Italy; Department of Urology, Karolinska University Hospital, Solna, Sweden.

Antonio Russo (A)

Department of Urology, IRCCS Ospedale San Raffaele, Milan, Italy; Department of Urology, Clinique Saint Augustin, Bordeaux, France.

Laura S Mertens (LS)

Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Luca Di Gianfrancesco (L)

Oncological Urology, IRCCS Veneto Institute of Oncology, Padua, Italy.

Carlo Andrea Bravi (CA)

Department of Urology, OLV Hospital, Aalst, Belgium; Orsi Academy, Ghent, Belgium.

Jonathan Vollemaere (J)

Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany.

Muhammad Abdeen (M)

Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany.

Mikolaj Mendrek (M)

Department of Urology, Pediatric Urology and Urologic Oncology, St. Antonius Hospital Gronau, Gronau, Germany.

Eirik Kjøbli (E)

Department of Urology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.

Stephan Buse (S)

Department of Urology, Alfried Krupp Krankenhaus, Essen, Germany.

Carl Wijburg (C)

Department of Urology Rijnstate Hospital, Arnhem, The Netherlands.

Alae Touzani (A)

Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France; Department of Urology, International Center of Oncology, Casablanca, Morocco.

Guillaume Ploussard (G)

Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France.

Alessandro Antonelli (A)

Department of Urology, University of Verona, Verona, Italy.

Laura Schwenk (L)

Department of Urology, University Hospital Basel, Basel, Switzerland.

Jan Ebbing (J)

Department of Urology, University Hospital Basel, Basel, Switzerland.

Nikhil Vasdev (N)

Hertfordshire and Bedfordshire Urological Cancer Centre, Department of Urology, Lister Hospital, Stevenage, UK.

Gabriel Froelicher (G)

Department of Urology, Cantonal Hospital Winterthur, Winterthur, Switzerland.

Hubert John (H)

Department of Urology, Cantonal Hospital Winterthur, Winterthur, Switzerland.

Abdullah Erdem Canda (AE)

Department of Urology, Koç University School of Medicine, Istanbul, Turkey.

Mevlana Derya Balbay (MD)

Department of Urology, Koç University School of Medicine, Istanbul, Turkey.

Marcel Stoll (M)

Department of Urology, Vinzenz Hospital, Hannover, Germany.

Sebastian Edeling (S)

Department of Urology, Vinzenz Hospital, Hannover, Germany.

Jorn H Witt (JH)

Department of Urology, Pediatric Urology and Urologic Oncology, St. Antonius Hospital Gronau, Gronau, Germany.

Sami-Ramzi Leyh-Bannurah (SR)

Department of Urology, Pediatric Urology and Urologic Oncology, St. Antonius Hospital Gronau, Gronau, Germany.

Stefan Siemer (S)

Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany.

Michael Stoeckle (M)

Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany.

Alexander Mottrie (A)

Department of Urology, OLV Hospital, Aalst, Belgium; Orsi Academy, Ghent, Belgium.

Frederiek D'Hondt (F)

Department of Urology, OLV Hospital, Aalst, Belgium; Orsi Academy, Ghent, Belgium.

Alessandro Crestani (A)

Oncological Urology, IRCCS Veneto Institute of Oncology, Padua, Italy.

Angelo Porreca (A)

Oncological Urology, IRCCS Veneto Institute of Oncology, Padua, Italy.

Hendrik van der Poel (H)

Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Urology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.

Karel Decaestecker (K)

Department of Urology, AZ Maria Middelares Hospital, Ghent, Belgium; Department of Urology, Ghent University Hospital, Ghent, Belgium.

Richard Gaston (R)

Department of Urology, Clinique Saint Augustin, Bordeaux, France.

N Peter Wiklund (N)

Department of Urology, Karolinska University Hospital, Solna, Sweden.

Abolfazl Hosseini (A)

Department of Urology, Karolinska University Hospital, Solna, Sweden. Electronic address: abolfazl.hosseini@ki.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH